semaglutide shortage ending The Is Ending: What's Next For Compounded Drugs? Semaglutide Shortage Ends: Compounded Versions

A key challenge in studying native GLP-1 is its extremely short in vivo half-life of approximately 12 minutes, owing to rapid inactivation by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal His-Ala dipeptide from GLP-1 to produce the inactive metabolite GLP-1(936)amide

This interaction might lead to changes in how the body regulates temperature, possibly causing hot flashes or other temperature-related side effects

BusseMBusseSMyintAMGosTDobrowolnyHMllerUJet al

Absolute contraindications include: Personal or family history of medullary thyroid carcinoma (MTC) Multiple endocrine neoplasia syndrome type 2 (MEN2) Known hypersensitivity to the medication or its components These are based on boxed warnings and prescribing information and should be treated as non-negotiable